Science News
from research organizations

Experts call to end secrecy surrounding approval of new drugs

Date:
March 31, 2010
Source:
BMJ-British Medical Journal
Summary:
Changes are urgently needed to end the secrecy surrounding approval of new drugs in Europe, argue experts.
Share:
       
FULL STORY

Changes are urgently needed to end the secrecy surrounding approval of new drugs in Europe, argue experts online in the British Medical Journal.

Questions about the benefits of the flu drug oseltamivir in otherwise healthy people have fuelled debate about the secrecy surrounding the documentation submitted by drug companies to obtain approval of new drugs, write Silvio Garattini and Vittorio Bertele' from the Mario Negri Institute for Pharmacological Research in Italy.

They believe that greater transparency "would open drug dossiers to evaluation by the scientific community and help independent interested parties define the benefit-risk profile of new medicines before they are allowed on to the market."

And they suggest that the recent movement of the European Medicines Agency (EMA) to the Health and Consumer Policy Directorate (DG Sanco) rather than the Enterprise and Industry Directorate "presents an opportunity to introduce more openness."

The industry considers it has the right to secrecy, in order to protect the substantial investments made to develop a new drug. But the authors argue that the public is an "essential partner" in new discoveries and therefore has "the right of access to all relevant information."

Secrecy about clinical data "implies undue exploitation of the rights of doctors and patients participating in the studies," they say.

Transparency of the regulatory system is also required "to overcome several dysfunctions in the drug industry's behaviour" and "cast light on deviations from trial protocols," they add.

The abolition of confidentiality would help make the system more transparent and enable clinicians and patients' representatives to obtain information on which to base constructive criticism, establishing public confidence and improving research in the industry itself, they explain.

Abolition of secrecy by EMA would also boost the regulatory authorities' credibility and show that patients' health has priority over industrial interests, they conclude.


Story Source:

The above post is reprinted from materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Garattini et al. Europe's opportunity to open up drug regulation. BMJ, 2010; 340 (mar30 2): c1578 DOI: 10.1136/bmj.c1578

Cite This Page:

BMJ-British Medical Journal. "Experts call to end secrecy surrounding approval of new drugs." ScienceDaily. ScienceDaily, 31 March 2010. <www.sciencedaily.com/releases/2010/03/100330210951.htm>.
BMJ-British Medical Journal. (2010, March 31). Experts call to end secrecy surrounding approval of new drugs. ScienceDaily. Retrieved July 1, 2015 from www.sciencedaily.com/releases/2010/03/100330210951.htm
BMJ-British Medical Journal. "Experts call to end secrecy surrounding approval of new drugs." ScienceDaily. www.sciencedaily.com/releases/2010/03/100330210951.htm (accessed July 1, 2015).

Share This Page: